IRIS

1.5 Abstract in Rivista: [1819] Home page tipologia

Sfoglia
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 521 a 540 di 1.819
Titolo Data di pubblicazione Autore(i) File
Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC) 1-gen-2007 Tomasello, G; Buti, S; Bosio, G; Stifani, I; Maestrelli, M; Brighenti, M; Porzio, R; Lazzarelli, S; Negri, F; Longarini, R; Passalacqua, R
Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC) 1-gen-2005 Passalacqua, R; Buzio, C; Dalla Chiesa, M; Camisa, R; Porta, C; Labianca, R; Frassoldati, A; Buti, S; Pezzuolo, D; Tomasello, G; Caminiti, C
Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG) 1-gen-2010 Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Lazzarelli, S
Terapia di mantenimento con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) nel Carcinoma Renale Metastatico (CRm). Trial multicentrico, prospettico, randomizzato di fase III 1-gen-2006 Vaglio, A; Passalacqua, R; Camisa, R; Dalla Chiesa, M; Labianca, R; Frassoldati, A; Porta, C; Buti, S; Caminiti, C; Bongiovanni, C; Alberici, F; Manna, C; David, S; Buzio, C
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs) 1-gen-2015 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; Di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Erythrocyte mean corpuscular volume change during pemetrexed treatment in advanced non small cell lung cancer patients 1-gen-2012 Buti, S; Bordi, P; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, Sg; Pilotto, S; Camisa, R; Ardizzoni, A
Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC) 1-gen-2012 Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, Lm; Facchini, G; Barile, C; Gernone, A; De Vivo, R; Pappagallo, G; Galligioni, E
Feasibility of two sequential dose-dense regimens with cisplatin-gemcitabine-paclitaxel (CGP) and HD-MVAC in patients with metastatic transitional cell carcinoma of the bladder 1-gen-2010 Brighenti, M; Liguigli, W; dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Lazzarelli, S; Poli, R; Donnini, M; Curti, A; Passalacqua, R; Potenzoni, D; Benecchi, L
Natural history of renal metastases to the pancreas: do not operate all and always? 1-gen-2014 Burattini, L; Santoni, M; Conti, A; Partelli, S; Porta, C; Sternberg, Cn; Procopio, G; Bracarda, S; Basso, U; De Giorgi, U; Derosa, L; Rizzo, M; Ortega, C; Massari, F; Milella, M; Buti, S; Cerbone, L; Montironi, R; Falconi, M; Santini, D; Cascinu, S
Impact of low doses of immunotherapy (LDI) with interleukin-2 (IL-2) and interferon alpha (IFNA) in metastatic renal cell cancer (MRCC) patients with different prognostic risk 1-gen-2006 Buti, S; Buzio, C; Vaglio, A; Bongiovanni, C; Alberici, F; Brighenti, M; Dalla Chiesa, M; Tomasello, G; Passalacqua, R
Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC) 1-gen-2007 Passalacqua, R; Buzio, C; Potenzoni, D; Buti, S; Labianca, R; Porta, C; Nastasi, P; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Alberici, F; Bongiovanni, C; Pezzuolo, D; Caminiti, C
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials 1-gen-2011 Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crino, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, Ef
The Criminal Law Protection of our Common Home: an Introduction to the VII AIDP Symposium for Young Penalists 1-gen-2020 Mazzacuva, Francesco; Gullo, Antonio; espinoza de los monteros de la parra, Manuel
Measures of High-Density Lipoprotein Function and Composition in Men and Women with Severe Aortic Valve Stenosis 1-gen-2021 Hafiane, Anouar; Favari, Elda; E Bortnick, Anna
The brain tissue reaction to blunt trauma: a field of possible cooperation between neuroanatomists and forensic pathologists 1-gen-2016 Cecchi, Rossana; Schirripa, Maria Laura; Banchini, Antonio; Vitale, Marco
LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial 1-gen-2021 Girard, N.; Ponce Aix, S.; Cedres, S.; Berghmans, T.; Burgers, S.; Toffart, A. C.; Popat, S.; Janssens, A.; Gervais, R.; Hochstenbag, M.; Silva, M.; Burger, I.; Prosch, H.; Stahel, R. A.; Govaerts, A-S.; Pochesci, A.; Neven, A.; Peters, S.
9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994) 1-gen-2020 Menis, J.; Bironzo, P.; Radj, G.; Greillier, L.; Monnet, I.; Livi, L.; Young, R.; Decroisette, C.; Cloarec, N.; Robinet, G.; Schott, R.; Califano, R.; De Marinis, F.; Mauer, M.; Pochesci, A.; Silva, M.; Caramella, C.; Dingemans, A-M.; Dive, C.; Besse, B.
An integrated system for mining relations among microRNAs, drugs and phenotypes 1-gen-2012 Pulvirenti, A; Giugno, R; Di Bella, S; Nigita, G; Macca, V; Giummarra, A; Garofalo, D; Caruso, G; Bonnici, V; Ferro, A
Core algorithms to search in biological structured data 1-gen-2012 Bonnici, V; Giugno, R; Pulvirenti, A; Shasha, D; Ferro, A
Human myeloma cells stimulate the receptor activator of NF-KB Ligad (RANKL) in T cells: Role of interleukin-7 1-gen-2002 Giuliani, N; Colla, S; Moroni, M; Bonomini, S; Lazzaretti, M; Sammarelli, G; La Monica, S; Bataille, R; Rizzoli, V
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 521 a 540 di 1.819
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile

Scopri
Tipologia
  • 1 Articolo su rivista1819
Autore
  • DI MARIO, Francesco242
  • BUTI, Sebastiano150
  • GIULIANI, Nicola130
  • ALBERTINI, Roberto87
  • SEBASTIANI, MARCO85
  • SCARPIGNATO, Carmelo75
  • AGNETTI, Aldo66
  • PARRINO, Liborio66
  • MUSOLINO, Antonino61
  • CARANO, Nicola60
Data di pubblicazione
  • 2020 - 2026208
  • 2010 - 2019847
  • 2000 - 2009537
  • 1990 - 1999175
  • 1980 - 198951
  • 1979 - 19791
Editore
  • ELSEVIER25
  • Elsevier17
  • SAGE PUBLICATIONS LTD17
  • DIKE GIURIDICA15
  • ASCO pubs11
  • ELSEVIER IRELAND LTD7
  • ASCO6
  • ELSEVIER SCIENCE INC5
  • SAGE5
  • SPRINGERNATURE4
Rivista
  • DIGESTIVE AND LIVER DISEASE101
  • GASTROENTEROLOGY100
  • ANNALS OF ONCOLOGY94
  • BLOOD91
  • HAEMATOLOGICA59
  • JOURNAL OF CLINICAL ONCOLOGY58
  • NEUROLOGICAL SCIENCES47
  • UNITED EUROPEAN GASTROENTEROLOGY ...46
  • ANNALS OF THE RHEUMATIC DISEASES36
  • EPILEPSIA26
Keyword
  • Helicobacter pylori10
  • epilepsy9
  • sclerosi sistemica6
  • Bioengineering5
  • Gastroenterology5
  • HCV5
  • temporal lobe epilepsy5
  • UV5
  • GERD4
  • Lungs4
Lingua
  • eng969
  • ita176
  • fre1
Accesso al fulltext
  • no fulltext1787
  • reserved26
  • open6